Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2015 1
2016 3
2017 1
2018 4
2019 2
2020 3
2021 7
2022 7
2023 3
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Clonal Hematopoiesis and Inflammation in the VasculaturE (CHIVE): a prospective, longitudinal cohort and biorepository.
Shannon ML, Heimlich JB, Olson S, Debevec A, Copeland Z, Kishtagari A, Vlasschaert C, Snider CA, Silver AJ, Brown D, Spaulding TP, Bhatta MR, Pugh K, Stockton SS, Ulloa J, Xu Y, Baljevic M, Moslehi J, Jahangir E, Ferrell PB Jr, Slosky DA MD, Bick AG, Savona MR. Shannon ML, et al. Blood Adv. 2024 Apr 12:bloodadvances.2023011510. doi: 10.1182/bloodadvances.2023011510. Online ahead of print. Blood Adv. 2024. PMID: 38608257
Multiomic Profiling of Human Clonal Hematopoiesis Reveals Genotype and Cell-Specific Inflammatory Pathway Activation.
Heimlich JB, Bhat P, Parker A, Jenkins MT, Vlasschaert C, Ulloa J, Van Amburg J, Potts CR, Olson S, Silver AJ, Ahmad A, Sharber B, Brown D, Hu N, van Galen P, Savona MR, Bick AG, Ferrell PB Jr. Heimlich JB, et al. Blood Adv. 2024 Mar 20:bloodadvances.2023011445. doi: 10.1182/bloodadvances.2023011445. Online ahead of print. Blood Adv. 2024. PMID: 38507736
Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk.
Kishtagari A, Khan MAW, Li Y, Vlasschaert C, Marneni N, Silver AJ, von Beck K, Spaulding T, Stockton S, Snider C, Sochacki A, Dorand D, Mack TM, Ferrell PB Jr, Xu Y, Bejan CA, Savona MR, Bick AG. Kishtagari A, et al. Among authors: ferrell pb jr. Blood Cancer J. 2024 Jan 15;14(1):6. doi: 10.1038/s41408-023-00974-9. Blood Cancer J. 2024. PMID: 38225345 Free PMC article.
PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis.
Moyo TK, Kishtagari A, Villaume MT, McMahon B, Mohan SR, Stopczynski T, Chen SC, Fan R, Huo Y, Moon H, Tang Y, Bejan CA, Childress M, Anderson I, Rawling K, Simons RM, Moncrief A, Caza R, Dugger L, Collins A, Dudley CV, Ferrell PB, Byrne M, Strickland SA, Ayers GD, Landman BA, Mason EF, Mesa RA, Palmer JM, Michaelis LC, Savona MR. Moyo TK, et al. Among authors: ferrell pb. Clin Cancer Res. 2023 Jul 5;29(13):2375-2384. doi: 10.1158/1078-0432.CCR-22-3192. Clin Cancer Res. 2023. PMID: 37036505 Clinical Trial.
Acly Deficiency Enhances Myelopoiesis through Acetyl Coenzyme A and Metabolic-Epigenetic Cross-Talk.
Greenwood DL, Ramsey HE, Nguyen PTT, Patterson AR, Voss K, Bader JE, Sugiura A, Bacigalupa ZA, Schaefer S, Ye X, Dahunsi DO, Madden MZ, Wellen KE, Savona MR, Ferrell PB, Rathmell JC. Greenwood DL, et al. Among authors: ferrell pb. Immunohorizons. 2022 Dec 1;6(12):837-850. doi: 10.4049/immunohorizons.2200086. Immunohorizons. 2022. PMID: 36547387 Free PMC article.
T cells specific for α-myosin drive immunotherapy-related myocarditis.
Axelrod ML, Meijers WC, Screever EM, Qin J, Carroll MG, Sun X, Tannous E, Zhang Y, Sugiura A, Taylor BC, Hanna A, Zhang S, Amancherla K, Tai W, Wright JJ, Wei SC, Opalenik SR, Toren AL, Rathmell JC, Ferrell PB, Phillips EJ, Mallal S, Johnson DB, Allison JP, Moslehi JJ, Balko JM. Axelrod ML, et al. Among authors: ferrell pb. Nature. 2022 Nov;611(7937):818-826. doi: 10.1038/s41586-022-05432-3. Epub 2022 Nov 16. Nature. 2022. PMID: 36385524 Free PMC article.
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, Dinner SN, Pigneux A, Montesinos P, Wang ES, Seiter KP, Wei AH, De Botton S, Arnan M, Donnellan W, Schwarer AP, Récher C, Jonas BA, Ferrell PB Jr, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard SM, Brevard J, Henrick P, Mohamed H, Cortes JE. Watts JM, et al. Among authors: ferrell pb jr. Lancet Haematol. 2023 Jan;10(1):e46-e58. doi: 10.1016/S2352-3026(22)00292-7. Epub 2022 Nov 10. Lancet Haematol. 2023. PMID: 36370742 Clinical Trial.
32 results